MAJI (Exousia Pro) Shares Outstanding (Basic Average): 13.52 Mil (As of Jan. 2021)


What is Exousia Pro Shares Outstanding (Basic Average)?

Exousia Pro MAJI +5.90% Shares Outstanding (Basic Average) is 13.52 Mil as of Jan. 2021.

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Exousia Pro's average basic shares outstanding for the quarter that ended in Jan. 2021 was 13.52 Mil.

Exousia Pro  (OTCPK:MAJI) Shares Outstanding (Basic Average) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Be Aware

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.

Exousia Pro Shares Outstanding (Basic Average) Related Terms

Exousia Pro Shares Outstanding (Basic Average) Historical Data

* Premium members only.

The historical data trend for Exousia Pro's Shares Outstanding (Basic Average) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Exousia Pro Shares Outstanding (Basic Average) Chart

Exousia Pro Annual Data
Trend Apr11 Apr12 Apr18 Apr19
Shares Outstanding (Basic Average)
4.19 3.36 5.71 12.49

Exousia Pro Quarterly Data
Oct11 Jan12 Apr12 Jul12 Oct12 Jan13 Oct17 Jan18 Apr18 Jul18 Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21
Shares Outstanding (Basic Average) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.49 12.49 12.49 13.27 13.52

Exousia Pro Shares Outstanding (Basic Average) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that exact time point. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

What does a Shares Outstanding (Basic Average) of 13.52 Mil mean?
Exousia Pro (MAJI) has a Shares Outstanding (Basic Average) of 13.52 Mil as of Jan. 2021. The average shares outstanding over two periods not accounting for dilutive securities like convertible bonds. View historical data on Exousia Pro and its competitors.
Is Exousia Pro's Shares Outstanding (Basic Average) too high?
Exousia Pro's current Shares Outstanding (Basic Average) is 13.52 Mil.
How does Exousia Pro's Shares Outstanding (Basic Average) compare to HCCH and GRNV?
Exousia Pro's Shares Outstanding (Basic Average) of 13.52 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (Basic Average) for a Biotechnology company?
A good Shares Outstanding (Basic Average) depends on the Biotechnology industry context. However, Shares Outstanding (Basic Average) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (Basic Average) mean?
A high Shares Outstanding (Basic Average) can signal that a stock is expensive relative to its fundamentals. The average shares outstanding over two periods not accounting for dilutive securities like convertible bonds. View historical data on Exousia Pro and its competitors. Exousia Pro's current Shares Outstanding (Basic Average) is 13.52 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Exousia Pro stock overvalued right now?
Exousia Pro (MAJI) has a current Shares Outstanding (Basic Average) of 13.52 Mil. The current Shares Outstanding (Basic Average) is 13.52 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (Basic Average) calculated?
Shares Outstanding (Basic Average) is calculated from a company's financial statements. For Exousia Pro (MAJI), the current Shares Outstanding (Basic Average) is 13.52 Mil as of Jan. 2021. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Exousia Pro Business Description

Address 7901 4th Street North, No. 23494, St. Petersburg, FL, USA, 33702
Exousia Pro Inc is a exosome-based biotechnology, develops and manufactures mammalian and plant-based exosomes using proprietary technologies for nucleic acid loading and targeted delivery to tissues and cells. The company is developing new ways to exploit the therapeutic potential of exosomes, initially focused in the field of oncology. The platform technology of the company also helps treating a broad spectrum of viral infections.